A functional variant in miR-143 promoter contributes to prostate cancer risk

Archives of Toxicology

Volumn 90, Issue 2, 2016, Pages 403-414

  Chu, Haiyan ^a,b   Zhong, Dongyan ^b,c   Tang, Jialin ^b,d   Li, Jie ^e   Xue, Yao ^a,b   Tong, Na ^a,b   Qin, Chao ^e   Yin, Changjun ^e   Zhang, Zhengdong ^a,b   Wang, Meilin ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

^c SOOCHOW UNIVERSITY   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Genetic susceptibility; KLK2; miR 143; Molecular epidemiology; Prostate cancer

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 2; MICRORNA 143; PEPTIDASE; UNCLASSIFIED DRUG; KLK2 PROTEIN, HUMAN; MICRORNA; MIRN143 MICRORNA, HUMAN;

AGED; ALLELE; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CANCER RISK; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CELL MOTION; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KALLIKREINS; MALE; MICRORNAS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS;

EID: 84958176563     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1396-2     Document Type: Article

References (55)

1. Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355. doi:10.1038/nature02871nature02871
2. Ambs S, Prueitt RL, Yi M et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68(15):6162–6170. doi:10.1158/0008-5472.CAN-08-0144
3. Andriole GL, Crawford ED, Grubb RL 3rd et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319. doi:10.1056/NEJMoa0810696
4. Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53(2):171–184. doi:10.1002/mnfr.200700511
5. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297
6. Becker C, Piironen T, Pettersson K et al (2000) Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. The Journal of urology 163(1):311–316
7. Chang A, Yousef GM, Scorilas A et al (2002) Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer 86(9):1457–1464
8. Chen C, Ridzon DA, Broomer AJ et al (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33(20):e179. doi:10.1093/nar/gni178
9. Chen X, Guo X, Zhang H et al (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28(10):1385–1392. doi:10.1038/onc.2008.474
10. Chitwood DH, Timmermans MC (2010) Small RNAs are on the move. Nature 467(7314):415–419. doi:10.1038/nature09351
11. Chow TF, Crow M, Earle T, El-Said H, Diamandis EP, Yousef GM (2008) Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol Chem 389(6):731–738. doi:10.1515/BC.2008.07110.1515/BC.2008.071
12. Clape C, Fritz V, Henriquet C et al (2009) miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 4(10):e7542. doi:10.1371/journal.pone.0007542
13. Clements JA, Willemsen NM, Myers SA, Dong Y (2004) The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 41(3):265–312. doi:10.1080/10408360490471931
14. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704–714. doi:10.1038/nrg2634
15. Deperthes D, Frenette G, Brillard-Bourdet M et al (1996) Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 17(6):659–665
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107
17. Kosik KS (2010) MicroRNAs and cellular phenotypy. Cell 143(1):21–26. doi:10.1016/j.cell.2010.09.008
18. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS (1997) Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57(15):3111–3114
19. Lin T, Dong W, Huang J et al (2009) MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol 181(3):1372–1380. doi:10.1016/j.juro.2008.10.149
20. Lose F, Batra J, O’Mara T et al (2013) Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic oncology 31(5):635–643
21. Lovgren J, Airas K, Lilja H (1999) Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur J Biochem 262(3):781–789
22. Luo X, Yang W, Ye DQ et al (2011) A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 7(6):e1002128. doi:10.1371/journal.pgen.1002128PGENETICS-D-10-00139
23. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS (1999) Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 81(3):438–442. doi:10.1002/(SICI)1097-0215(19990505)81:3<438:AID-IJC18>3.0.CO;2-U
24. Mize GJ, Wang W, Takayama TK (2008) Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol Cancer Res 6(6):1043–1051. doi:10.1158/1541-7786.MCR-08-0096
25. Noguchi S, Yasui Y, Iwasaki J et al (2013) Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett 328(2):353–361. doi:10.1016/j.canlet.2012.10.017
26. Obiezu CV, Diamandis EP (2005) Human tissue kallikrein gene family: applications in cancer. Cancer Lett 224(1):1–22. doi:10.1016/j.canlet.2004.09.024
27. Recker F, Kwiatkowski MK, Piironen T et al (2000) Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55(4):481–485
28. Rehault S, Monget P, Mazerbourg S et al (2001) Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 268(10):2960–2968
29. Riegman PH, Vlietstra RJ, van der Korput HA, Romijn JC, Trapman J (1991) Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol 76(1–3):181–190
30. Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10(6):389–402. doi:10.1038/nrc2867
31. Samaan S, Lichner Z, Ding Q et al (2014) Kallikreins are involved in an miRNA network that contributes to prostate cancer progression. Biol Chem 395(9):991–1001
32. Schaefer A, Jung M, Mollenkopf HJ et al (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126(5):1166–1176. doi:10.1002/ijc.24827
33. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. doi:10.1056/NEJMoa0810084
34. Sevignani C, Calin GA, Nnadi SC et al (2007) MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA 104(19):8017–8022. doi:10.1073/pnas.0702177104
35. Shahi P, Loukianiouk S, Bohne-Lang A et al (2006) Argonaute–a database for gene regulation by mammalian microRNAs. Nucleic acids res 34(database issue):D115-8. doi:10.1093/nar/gkj093
36. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138
37. Smale ST, Kadonaga JT (2003) The RNA polymerase II core promoter. Annu Rev Biochem 72:449–479. doi:10.1146/annurev.biochem.72.121801.161520121801.161520
38. Sun Z, Pan J, Balk SP (1997) Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res 25(16):3318–3325
39. Szczyrba J, Loprich E, Wach S et al (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8(4):529–538. doi:10.1158/1541-7786.MCR-09-0443
40. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y (2009) Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 77(1):12–21. doi:10.1159/000218166
41. Tong AW, Fulgham P, Jay C et al (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16(3):206–216. doi:10.1038/cgt.2008.77
42. Ugras S, Brill E, Jacobsen A et al (2011) Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res 71(17):5659–5669. doi:10.1158/0008-5472.CAN-11-0890
43. Vrba L, Garbe JC, Stampfer MR, Futscher BW (2011) Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res 21(12):2026–2037. doi:10.1101/gr.123935.111
44. Wach S, Nolte E, Szczyrba J et al (2012) MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130(3):611–621. doi:10.1002/ijc.26064
45. Weis L, Reinberg D (1992) Transcription by RNA polymerase II: initiator-directed formation of transcription-competent complexes. FASEB J 6(14):3300–3309
46. White NM, Bui A, Mejia-Guerrero S et al (2010a) Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol Chem 391(4):411–423. doi:10.1515/BC.2010.041
47. White NM, Chow TF, Mejia-Guerrero S et al (2010b) Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer 102(8):1244–1253. doi:10.1038/sj.bjc.6605634
48. White NM, Youssef YM, Fendler A, Stephan C, Jung K, Yousef GM (2012) The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol Chem 393(5):379–389. doi:10.1515/hsz-2011-0246/j/bchm.2012.393.issue-5/hsz-2011-0246/hsz-2011-0246.xml
49. Xu B, Niu X, Zhang X et al (2011a) miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350(1–2):207–213. doi:10.1007/s11010-010-0700-6
50. Xu Y, Liu L, Liu J et al (2011b) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128(2):412–417. doi:10.1002/ijc.25342
51. Xue Y, Wang M, Kang M et al (2013) Association between lncrna PCGEM1 polymorphisms and prostate cancer risk. Prostate cancer and prostatic diseases 16(2):139–144. doi:10.1038/pcan.2013.6
52. Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51(14):3748–3752
53. Young CY, Andrews PE, Montgomery BT, Tindall DJ (1992) Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31(3):818–824
54. Zhang Y, Wang Z, Chen M et al (2012) MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 11:23. doi:10.1186/1476-4598-11-23
55. Zhou X, Ruan J, Wang G, Zhang W (2007) Characterization and identification of microRNA core promoters in four model species. PLoS Comput Biol 3(3):e37. doi:10.1371/journal.pcbi.0030037